Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Norcuron; Belgium: Norcuron; Cyprus: Norcuron; Czech Republic: Norcuron; Finland: Norcuron; France: Norcuron; Germany: Norcuron, Vecuronium; Greece: Norcuron; Ireland: Norcuron; Italy: Norcuron; Luxembourg: Norcuron; Netherlands: Norcuron; Poland: Norcuron; Portugal: Norcuron; Romania: Norcuron; Slovakia: Norcuron; Slovenia: Norcuron; Spain: Norcurón, Vecuronio; Sweden: Norcuron; UK: Norcuron.

North America

Canada: Vecuronium; USA: Vecuronium.

Latin America

Argentina: Galarén, Gobbicuronio, Rivecrum, Vecural, Vecurón, Vecuronio; Brazil: Norcuron, Vecuron; Mexico: Bromivec, Nodescrón, Norcurón, Vecuronio.


Japan: Musculax, Muscurate.

Drug combinations


Vecuronium Bromide: C~34~H~57~BrN~2~O~4~. Mw: 637.73. (1) Piperidinium, 1-[(2β,3α,5α,16β,17β)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstan-16-yl]-1-methyl-, bromide; (2) 1-(3α,17β-Dihydroxy-2β-piperidino-5α-androstan-16β,5α-yl)-1-methylpiperidinium bromide, diacetate. CAS-50700-72-6 (1984).

Pharmacologic Category

Neuromuscular Blocking Agents, Nondepolarizing. (ATC-Code: M03AC03).

Mechanism of action

Blocks acetylcholine from binding to receptors on motor endplate inhibiting depolarization.

Therapeutic use

Adjunct to general anesthesia to facilitate endotracheal intubation and to relax skeletal muscles during surgery. Facilitation of mechanical ventilation.

Pregnancy and lactiation implications

Use in cesarean section reported. Excretion in breast milk unknown (use with caution in nursing women).

Unlabeled use


Hypersensitivity to vecuronium or any component of the formulation.

Warnings and precautions

Does not counteract bradycardia produced by anesthetics/vagal stimulation. Cross-sensitivity with other neuromuscular-blocking agents may occur (use extreme caution in previous anaphylactic reactions). Resistance may occur in burn patients (>30% of body) for period of 5-70 days postinjury. Conditions which may antagonize neuromuscular blockade (alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, and diabetes mellitus) may result in antagonism of neuromuscular blockade. Conditions which may potentiate neuromuscular blockade (electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, and hepatic failure) may result in potentiation of neuromuscular blockade. Use with caution in hepatic or renal impairment, and in the elderly. Resistance may occur in immobilized patients. Vecuronium produces minimal, if any, histamine release. Does not relieve pain or produce sedation.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart